Bioxytran to Internally Develop Novel Carbohydrate Galectin Inhibitor to Eliminate COVID-19 in Patients
Galectin research required to initiate clinical trials, subject to funding, will be based on internal development as opposed to a license as previously reported.Bioxytran Releases Details on a Novel Carbohydrate Galectin Inhibitor Designed to Eliminate COVID-19 in Patients
Company releases new COVID-19 slide deck on website. Bioxytran Positioned to Detect and Treat Stroke and Neuropathologies
Journal Article correlates different neurological pathologies with Brain Metabolic Score and examines a neurological case study.Bioxytran Seeking Partners for Late Stage Treatment of Wuhan Coronavirus Using BXT-25
BXT-25 has the potential to treat late stage acute respiratory distress syndrome (ARDS) which is the leading cause of death in coronavirus patients.Bioxytran's Mdx Viewer Demonstrates Early Warning Signs of Brain Health During Cardiovascular Surgeries
MDX Viewer use during open heart surgery is an essential vital sign that could mitigate the risk of brain damage caused by prolonged oxygen deprivation during perioperative cardiovascular procedures and validates tissue oxygenation in the brain for stoke patients.Bioxytran Now Using Paradigm Changing Vital Sign That Can Measure Real-Time Tissue Oxygen Balance in Emergency Medicine
BIOXYTRAN, INC. a developmental stage biotechnology company with a pipeline of anti-necrosis drugs designed to treat hypoxia by delivering a small molecule carrying oxygen to the brain of stroke victims announced today that the Journal of Emergency Medicine and Care published a peer-reviewed article that describes a revolutionary new vital sign called the Tissue Metabolic Score (TMS). The monitoring device measures mitochondrial function and microcirculation hemodynamics that are integrated and displays the TMS and plots it versus time. The article, entitled "Oxygen Balance Homeostasis and Tissue Metabolic Score (TMS) of Patients In Emergency and Critical Care Medicine" was published by Prof. Avraham Mayevsky in Volume 1, Issue 2 in the Journal of Emergency Medicine and Care. The FDA approved monitoring device -CritiView- was renamed by MDX Life Sciences to the MDX Viewer. Bioxytran has an exclusive licensing agreement with MDX Life Sciences to measure cellular health.Bioxytran Using Paradigm Changing Vital Sign That Can Measure Real Time Tissue Oxygen Balance in Emergency Medicine
BIOXYTRAN, INC., a developmental stage biotechnology company with a pipeline of anti-necrosis drugs designed to treat hypoxia by delivering a small molecule carrying oxygen to the brain of stroke victims announced today that the Journal of Emergency Medicine and Care published a peer-reviewed article that describes a revolutionary new vital sign called the Tissue Metabolic Score (TMS). The monitoring device measures mitochondrial function and microcirculation hemodynamics that are integrated and displays the TMS and plots it versus time. The article, entitled "Oxygen Balance Homeostasis and Tissue Metabolic Score (TMS) of Patients In Emergency and Critical Care Medicine" was published by Prof. Avraham Mayevsky in Volume 1, Issue 2 in the Journal of Emergency Medicine and Care. The FDA approved monitoring device -CritiView- was renamed by MDX Life Sciences to the MDX Viewer. Bioxytran has an exclusive licensing agreement with MDX Life Sciences to measure cellular health. Bioxytran Inc. Announces Appointment of Ex Bristol-Myers Squibb Executive to Scientific Advisory Board
BIOXYTRAN, INC., a developmental stage biotechnology company developing a pipeline of anti-necrosis drugs designed to treat hypoxia by delivering a small molecule carrying oxygen to the brain of stroke victims announced today that it has retained Juan Carlos Lopez-Talavera, MD, PhD to join Bioxytran's Scientific Advisory Board to manage the company's FDA regulatory application process for Bioxytran's flagship drug, BXT-25.